NASDAQ-NMS:BMRN

BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV

Retrieved on: 
Wednesday, May 8, 2024
Bank of America, BofA Securities, BMRN, Conference, SAN, BioMarin Pharmaceutical

SAN RAFAEL, Calif., May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 10:00am PT / 1:00pm ET, in Las Vegas, Nevada.

Key Points: 
  • SAN RAFAEL, Calif., May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 10:00am PT / 1:00pm ET, in Las Vegas, Nevada.
  • An audio webcast of the presentation will be available live.
  • You can access the webcast at: https://investors.biomarin.com/ .
  • An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET

Retrieved on: 
Wednesday, April 10, 2024
BMRN, Webcast, SAN, BioMarin Pharmaceutical, Interest

SAN RAFAEL, Calif., April 10, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24, at 4:30 p.m.

Key Points: 
  • SAN RAFAEL, Calif., April 10, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24, at 4:30 p.m.
  • ET to discuss first quarter 2024 financial results and provide a general business update.
  • U.S. / Canada Replay Dial-in Number: 800-770-2030
    Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/ .
  • A replay of the call will be archived on the site for one week following the call.

New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

Retrieved on: 
Tuesday, March 12, 2024
Quality of life, ACMG, SAN, Medical genetics, AGV, American College, Observation, Achondroplasia, Hypochondroplasia, Medicine

SAN RAFAEL, Calif., March 12, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO® (vosoritide) in children with hypochondroplasia, will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024. Researchers will also present data from Phase 2 and Phase 3 studies of the medicine in children with achondroplasia, including results that demonstrate VOXZOGO's positive impact on quality of life. 

Key Points: 
  • Andrew Dauber, M.D., will present positive results from his investigator-sponsored Phase 2 study of VOXZOGO in children with hypochondroplasia.
  • The annualized growth velocity (AGV) increased from 5.12 cm/year during the observation period to 6.93 cm/year during the treatment period (mean difference: 1.81 cm/year, p
  • In late 2023, BioMarin launched the pivotal clinical trial program studying the safety and efficacy of VOXZOGO in children with hypochondroplasia.
  • "Our studies showed that increasing height with long-term administration of VOXZOGO can result in meaningful improvements in quality-of-life measures for children with achondroplasia."

BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

Retrieved on: 
Thursday, March 7, 2024
Cristin, SAN, School, Ophthalmology, Roche, Growth, Public health, MBA, Molecular biology, Postgraduate education, University, Haemophilia, Business, BioMarin Pharmaceutical, Triple accreditation, Patient, Infection, BMRN

SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer. Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer.

Key Points: 
  • SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer.
  • Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer.
  • Ms. Hubbard is a proven leader who brings to BioMarin more than 20 years of experience in the biopharmaceutical and diagnostics industries.
  • He has worked at BioMarin for more than 18 years, including 11 as chief commercial officer.

BioMarin Scheduled to Participate in March Investor Conferences

Retrieved on: 
Friday, March 1, 2024
SAN, BioMarin Pharmaceutical, Conference, BMRN, Pharmaceutical industry

SAN RAFAEL, Calif., March 1, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management is scheduled to participate in four upcoming investor conferences in March.

Key Points: 
  • SAN RAFAEL, Calif., March 1, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management is scheduled to participate in four upcoming investor conferences in March.
  • Cowen 44th Annual Healthcare Conference (Boston, MA)
    Leerink Partners Global BioPharma Conference (Miami, FL)
    Jefferies Biotech on the Bay Summit (Miami, FL)
    Barclays 26th Annual Global Healthcare Conference (Miami, FL)
    The live webcast of the fireside chat can be accessed by visiting BioMarin's website at https://investors.biomarin.com/ .
  • A webcast replay will be available through the Company's website for a limited time following the conferences.

BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET

Retrieved on: 
Thursday, February 8, 2024
BioMarin Pharmaceutical, SAN, BMRN, Webcast, Interest

SAN RAFAEL, Calif., Feb. 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 22, at 4:30 p.m.

Key Points: 
  • SAN RAFAEL, Calif., Feb. 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 22, at 4:30 p.m.
  • ET to discuss fourth quarter and full-year 2023 financial results and provide a general business update.
  • U.S. / Canada Replay Dial-in Number: 800-770-2030
    Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/ .
  • A replay of the call will be archived on the site for one week following the call.

BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress

Retrieved on: 
Tuesday, February 6, 2024
Injection, SAN, BioMarin Pharmaceutical, Congress, Hemostasis, Safety, ABR, Central European Time, Bleeding, Risk, Haemophilia, Pharmaceutical industry

SAN RAFAEL, Calif., Feb. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) will be presented at the 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress, Feb. 6-9, 2024.

Key Points: 
  • SAN RAFAEL, Calif., Feb. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) will be presented at the 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress, Feb. 6-9, 2024.
  • The majority of participants maintained hemostasis, with only two of the seven participants in the study returning to regular prophylaxis, and no new safety signals emerged.
  • These data will be presented as a poster presentation from 6:30-7:30 p.m. Central European Time (CET) on Wednesday, Feb. 7.
  • "We are pleased to present data showing the impact of one-time treatment with ROCTAVIAN over seven years following the infusion, underscoring the potential of gene therapy to make a meaningful and long-lasting impact for people living with severe hemophilia A."

BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA

Retrieved on: 
Wednesday, January 3, 2024
BMRN, Conference, BioMarin Pharmaceutical, SAN

SAN RAFAEL, Calif., Jan. 3, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 42nd Annual J.P. Morgan Conference on Monday January 8, 2024, at 10:30 am PT / 1:30 pm ET, in San Francisco, California.

Key Points: 
  • SAN RAFAEL, Calif., Jan. 3, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 42nd Annual J.P. Morgan Conference on Monday January 8, 2024, at 10:30 am PT / 1:30 pm ET, in San Francisco, California.
  • An audio webcast of the presentations will be available live.
  • You can access the webcasts at: https://investors.biomarin.com/ .
  • An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

BioMarin Announces Governance Enhancements and Value Creation Initiatives

Retrieved on: 
Wednesday, December 20, 2023
Adverum Biotechnologies, University, Ambit Biosciences, Daiichi Sankyo, Hill-Rom, Indiana University, Harvard Law School, Baxter, Acceleration, Strategy, Palmer, Pfizer, Biotechnology Innovation Organization, Invacare, Eli Lilly, Hospira, Pediatrics, Chairperson, The Nature Conservancy, Genzyme, American Cancer Society, Therapy, Goldman Sachs, M.B.A, BMRN, ImmunoGen, DSM-IV codes, Shire (pharmaceutical company), IPO, Patient, Proteostasis, BioMarin Pharmaceutical, Corporate development, Dentsply Sirona, Senior, Syneos Health, Iovance Biotherapeutics, Sclerosis, Acquisition, SAN, CIO, Eli Lilly and Company, Interim, Bristol Myers Squibb, Information technology, Management

SAN RAFAEL, Calif., Dec. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation.

Key Points: 
  • SAN RAFAEL, Calif., Dec. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder value creation.
  • "Today's announcements will strengthen our ability to drive better outcomes for patients with genetic diseases and deliver value to all stakeholders.
  • BioMarin plays a pivotal role in the treatment of genetic diseases thanks to its globally leading rare-disease portfolio.
  • We believe the changes announced today put BioMarin in the best position to realize its full potential, and we support Alexander Hardy as the right leader for this chapter of BioMarin's value creation story.

BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer

Retrieved on: 
Wednesday, November 1, 2023
Science, DSM-IV codes, Pathogenesis, Haemophilia, Ophthalmology, Organization, Research, Achondroplasia, Enzyme replacement therapy, Growth, Novartis, Neuroscience, Roche, GSK, JJ, Patient, BioMarin Pharmaceutical, Management, Pharmaceutical industry, Shareholder, Genentech

SAN RAFAEL, Calif., Nov. 1, 2023  /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, announced today that Alexander Hardy has been named president and chief executive officer, succeeding Jean-Jacques Bienaimé, who will retire as chairman and CEO effective December 1, 2023. Mr. Hardy, currently the CEO of Genentech, will also serve as a director on BioMarin's board of directors. Richard A. Meier, BioMarin's lead independent director, will assume the role of chair of the board of directors.

Key Points: 
  • Mr. Hardy, currently the CEO of Genentech, will also serve as a director on BioMarin's board of directors.
  • Richard A. Meier, BioMarin's lead independent director, will assume the role of chair of the board of directors.
  • Mr. Hardy, 55, brings more than 30 years of experience in the global healthcare and biotechnology industries, most recently serving as CEO of Genentech, a member of the Roche Group.
  • Thanks to JJ, BioMarin is ideally positioned for its next chapter with Alexander at the helm."